Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Biejia-Ruangan Compound on Survival Rate and Recurrence Rate of Hepatocellular Carcinoma After Radical Treatment

NCT06923176 is registered in ClinicalTrials.gov with Zhiyun Yang as lead sponsor.

NCT NCT06923176
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06923176 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Biejia-Ruangan Compound on Survival Rate and Recurrence Rate of Hepatocellular Carcinoma After Radical Treatment
Lead sponsor
Zhiyun Yang
Phase
Phase 4
Overall status
Not yet recruiting
Start date
April 19, 2025
Completion date
April 30, 2031
Enrollment
704 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma (hcc)